Xechem International, Inc., a development stage biopharmaceutical company, engages in the research, development, and limited production of generic drugs from natural sources. The company operates primarily through its subsidiary, Xechem Inc., which engages in applying its extraction, isolation, and purification technology to the production and manufacture of paclitaxel (Taxol). Paclitaxel is an anticancer compound used for the treatment of ovarian, breast, and small cell lung cancers, as well as AIDS related Kaposi sarcomas. The companys other products include Nicosan/Hemoxin, a nutraceutical product, which has received orphan drug designation from U.S.-FDA; Vancomycin; and Bleomycin. In addition, the company engages in the research and development of other generic compounds, by microbial fermentation or semisynthesis; and on the development of drugs from sources derived from Chinese, Indian, and other traditional medicinal plants in the anticancer, antifungal, anti-viral, anti-inflammatory, anti-aging, and memory enhancing areas.
